Close Menu

NEW YORK (GenomeWeb) – Bio-Techne and NanoString Technologies said today that they are partnering to create a workflow for spatial genomics research uniting Bio-Techne's RNAscope reagent portfolio with NanoString's GeoMx RNA assays and digital spatial profiling instrument.

Under the terms of the agreement, NanoString and Bio-Techne will develop, validate, and comarket protocols that combine RNAscope reagents and GeoMx assays. In addition, NanoString will provide RNAscope research services through its GeoMx DSP Technology Access Program.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.